GSK Plus Sanofi: The COVID-19 Vaccine Dream Team?

Tried-And-Tested Platforms Could Pay Off

 
• By Andrew McConaghie

While not promising the fastest development time that the world craves, the combined experience and scale of the two vaccine giants bodes well.

GSK_HQ
By pooling its expertise and manufacturing scale with rivals Sanofi on the COVID-19 vaccine, GSK is increasing the odds of success

More from Business

More from Scrip